Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings, Inc., the synthetic biology company that came public through a merger with Soaring Eagle Acquisition Corp. (Nasdaq: SRNG), filed an 8-K with the Securities and Exchange Commission on June 13, 2025. Soaring Eagle, sponsored by Eagle Equity Partners and led by veteran media financiers Harry Sloan and Jeff Sagansky, completed its SPAC IPO in 2021 before closing its business combination with Ginkgo Bioworks, a life sciences platform company focused on cell programming and industrial biotechnology. The filing marks continued post-merger disclosure activity for the de-SPAC'd entity operating in the synthetic biology sector. Sign up for SpacDesk to access full filing histories, sponsor profiles, and real-time data on SRNG and the broader SPAC universe.